Option restructuring by Alamar Biosciences (ALMR) board director
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Alamar Biosciences director Frank Witney reported internal option restructurings related to the company’s share reclassification. On April 20, 2026, six Form 4 transactions with code J moved stock options between underlying Class B Common Stock and Common Stock at no transaction price.
The filing shows options for 124,069 shares at an exercise price of $7.60 expiring on January 14, 2036, 33,085 shares at $3.10 expiring on April 15, 2035, and 49,627 shares at $0.59 expiring on April 20, 2031. A footnote states each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Witney Frank
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Stock Option (Right to Buy) | 49,627 | $0.00 | -- |
| Other | Stock Option (Right to Buy) | 49,627 | $0.00 | -- |
| Other | Stock Option (Right to Buy) | 33,085 | $0.00 | -- |
| Other | Stock Option (Right to Buy) | 33,085 | $0.00 | -- |
| Other | Stock Option (Right to Buy) | 124,069 | $0.00 | -- |
| Other | Stock Option (Right to Buy) | 124,069 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct, null)
Footnotes (1)
- Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. Fully vested. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date. Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.
Key Figures
Total restructuring shares: 413,562 shares
Option grant 1 size: 124,069 shares
Option grant 1 strike: $7.60 per share
+5 more
8 metrics
Total restructuring shares
413,562 shares
J-code restructuring transactions summary
Option grant 1 size
124,069 shares
Stock option at $7.60 exercise price, expiring January 14, 2036
Option grant 1 strike
$7.60 per share
Exercise price for 124,069-share option grant
Option grant 2 size
33,085 shares
Stock option at $3.10 exercise price, expiring April 15, 2035
Option grant 2 strike
$3.10 per share
Exercise price for 33,085-share option grant
Option grant 3 size
49,627 shares
Stock option at $0.59 exercise price, expiring April 20, 2031
Option grant 3 strike
$0.59 per share
Exercise price for 49,627-share option grant
Transaction date
April 20, 2026
All six J-code derivative transactions
Key Terms
Stock Option (Right to Buy), Class B Common Stock, initial public offering, reclassified, +2 more
6 terms
Stock Option (Right to Buy) financial
""security_title": "Stock Option (Right to Buy)""
Class B Common Stock financial
""underlying_security_title": "Class B Common Stock""
A class B common stock is one of multiple types of a company’s ordinary shares that carries specific rights—often different voting power or dividend priority—compared with other classes. For investors it matters because those differences affect how much influence you have over company decisions, the income you might receive, and how freely the shares trade; think of it like owning a car with different keys: some keys let you start the engine and open the trunk, others only unlock the door.
initial public offering financial
"prior to the completion of the initial public offering of the Issuer's Common Stock"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
reclassified financial
"Each share of Class B Common Stock was reclassified into one share of Common Stock"
vest in equal monthly installments financial
"The shares subject to the option vest in equal monthly installments over 48 months"
continuous service financial
"subject to the reporting person's continuous service as of each such vesting date"
FAQ
What did Alamar Biosciences (ALMR) director Frank Witney report in this Form 4?
Frank Witney reported six option restructuring transactions coded J on April 20, 2026. These moved stock options between Class B Common Stock and Common Stock with no transaction price, reflecting internal changes tied to the company’s share reclassification before its initial public offering.
What are the exercise prices of Frank Witney’s Alamar Biosciences (ALMR) stock options?
Witney’s options have exercise prices of $7.60, $3.10 and $0.59 per share. Each price applies to a separate option grant, with differing share amounts and expiration dates, providing multiple strike levels for potential future exercises of Alamar Biosciences common stock.
When do Frank Witney’s Alamar Biosciences (ALMR) stock options expire?
The options expire on three different dates: January 14, 2036, April 15, 2035 and April 20, 2031. Each expiration date corresponds to a distinct grant with its own exercise price and share count, defining how long Witney retains the right to buy shares.
What does the Class B Common Stock reclassification mean for Alamar Biosciences (ALMR) options?
A footnote explains that each share of Class B Common Stock was reclassified into one share of Common Stock before the initial public offering. The option records show corresponding positions in both classes, indicating the restructuring aligns option rights with the new single common stock class.
Are Frank Witney’s Alamar Biosciences (ALMR) options vested or subject to future vesting?
One footnote states a grant is fully vested, while others vest over time. For example, some options vest in equal monthly installments over 48 months from January 1, 2025, and another grant vests 25% on January 15, 2027 with monthly vesting thereafter, contingent on continuous service.